Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer. - Wikidata - wikimedia - TriplyDB

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.

http://www.wikidata.org/entity/Q34038059

about

Regulatory T-cell density and cytotoxic T lymphocyte density are associated with complete response to neoadjuvant paclitaxel and carboplatin chemoradiotherapy in gastric cancer

P2860

Q57787105-C3C8E185-5E1B-48C1-8F10-D0D6CDC2B3B4

P2860

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.

http://www.wikidata.org/entity/Q34038059

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@ast

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@en

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@nl

type

label

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@ast

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@en

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@nl

prefLabel

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@ast

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@en

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@nl

P1433

Q34038059-81EB80BF-9F1F-4DC9-BB91-B896E406642C

P1476

Q34038059-5021A6E3-5F50-48A8-9498-BFEE01AA4740

P2093

Q34038059-0D457BBD-EF12-45C4-A051-5C68726020A4

Q34038059-19507AD3-404C-46F3-BE56-E19B977F1541

Q34038059-293086E4-0917-46CF-907D-97FF5C52C687

Q34038059-43909C26-EEF0-4FF7-AAB8-73F1FD23FB91

Q34038059-6BB79A9D-2EF8-494E-8E12-E393C518A72D

Q34038059-BDC83362-2FF5-4FA8-A964-0FD4D63F8502

Q34038059-D3FEB970-5726-470F-8C26-103DACA97C07

P2860

Q34038059-018D716A-F450-4246-B605-08E39DAE9104

Q34038059-1A90A43F-1D50-4371-9A09-5A745D681AF8

Q34038059-3288AB8A-8CE9-4366-A775-555D9DBF5E64

Q34038059-3371599B-8556-46E1-95F3-6110F2CF0233

Q34038059-4705567F-84D7-425F-BEC0-E19058362F80

Q34038059-4E247B7C-0BE0-4300-83DA-9E0C0FFE3417

Q34038059-69356C5E-A6ED-41E7-AAD6-3C1E6406ABAC

Q34038059-6E984061-BF95-4810-B0DA-D9C545041330

Q34038059-79267147-5CE1-4FE4-9412-755CECCBA5A4

Q34038059-CBAF1DF0-34F2-492D-99A9-0B97830985C1

P304

Q34038059-740FC13E-4F4C-4D4F-A33E-78D331EDA694

P31

Q34038059-3A557F54-0563-4AE8-B04F-8AAF71B2D9C6

Q34038059-8bb87d58-060f-4166-8c9c-5ca21008bfb6

P356

Q34038059-94E1696B-FA80-4214-90C0-BF07C2BAA8C3

P433

Q34038059-B4C19FEE-E7D0-4F53-9B80-E5BD3B8A4F61

P478

Q34038059-8F109E0B-4D66-40AF-AE59-33BD2BA01AEB

P577

Q34038059-987F909E-504A-4245-B678-C23A5014D9D5

P5875

Q34038059-89F477F0-1A2A-426A-B1FC-D6444813BE6A

P698

Q34038059-590113DC-367D-4894-B748-FA9528A48D3B

P932

Q34038059-3602FFA1-F04F-4F7B-B4AC-EE6EB341C708

P356

P1433

Case reports in oncology

P1476

Safety and Feasibility of Carb ...... nt Therapy for Gastric Cancer.

@en

P2093

Anthony F Shields

http://www.w3.org/2001/XMLSchema#string

Bassel F El-Rayes

http://www.w3.org/2001/XMLSchema#string

Lance K Heilbrun

http://www.w3.org/2001/XMLSchema#string

Mohammad Mobayed

http://www.w3.org/2001/XMLSchema#string

Philip A Philip

http://www.w3.org/2001/XMLSchema#string

Raghu Venkatramanamoorthy

http://www.w3.org/2001/XMLSchema#string

Tara Washington

http://www.w3.org/2001/XMLSchema#string

P2860

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction.

Analysis of 154 actual five-year survivors of gastric cancer.

Gastric adenocarcinoma: review and considerations for future directions.

Gastric cancer--patterns of relapse after surgical resection.

Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.

Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).

Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.

Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.

P304

220-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000250082

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45828262

http://www.w3.org/2001/XMLSchema#string

P698

20737041

http://www.w3.org/2001/XMLSchema#string

P932

2914386

http://www.w3.org/2001/XMLSchema#string